Intas Pharmaceuticals files PGR petition challenging Atossa's endoxifen patent

ATOSSA THERAPEUTICS, INC.

Intas Pharmaceuticals filed a Post-Grant Review petition with USPTO challenging Atossa's U.S. Patent No. 11,572,334.
Patent covers methods for making and using endoxifen.
Atossa intends to contest the PGR and believes the patent is valid and enforceable.
No assurance of prevailing; Intas will be estopped from raising certain arguments in future litigation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.